Stem Cell & Regenerative Medicine Stocks

Last updated: September 16, 2026 (ET). Tickers verified as publicly traded as of this date. Listings and pipelines change – always re-check exchange status and company filings before acting.

Investing in Regenerative Medicine & Stem Cells

Welcome to the Stem Cell Tracker stocks page: an educational catalog of publicly traded companies meaningfully engaged in stem cell research, regenerative medicine, cell therapy, or gene-edited cell therapies – in the United States and abroad.

Stem cells – cells that can renew themselves and, in many cases, give rise to specialized tissue types – sit at the center of efforts to repair or replace damaged organs and modulate inflammation and immune responses. Activity spans pure-play developers of mesenchymal stromal cells (MSCs), induced pluripotent stem cell (iPSC)-derived products, and embryonic stem cell-derived lineages, as well as larger biotechs and pharma companies advancing commercial or late-stage cell therapies (including gene-edited autologous cell products).

Interest in the space has grown as more programs reach late-stage trials and as a small number of cell therapies have secured regulatory approvals. That does not mean every listed company will succeed commercially. Clinical failure rates remain high, capital needs are large, and share prices often move sharply on trial readouts, FDA decisions, financing news, and partnership updates. Investing in these companies carries significant risk.

This page groups companies for easier browsing and education. It is not a buy list, a ranking, or a prediction of future returns.

How this list is organized

U.S.-listed names appear first; dual-listed or OTC names are noted. Prefer accuracy over a long list: many “stem cell” microcaps have weak pipelines or limited disclosure.

Pure-play / focused stem cell & regenerative companies (U.S.-listed)

Pure-play

OTC / microcap (higher liquidity & disclosure risk)

Broader biotech / pharma with major stem cell or cell-therapy programs

Broader biotech

These companies are not pure-play stem-cell stocks; regenerative or gene-edited cell therapy is one part of a larger business.

Related tools & suppliers (labeled – not therapeutic developers)

Tools & suppliers

These firms supply reagents, instruments, or manufacturing systems used in cell and gene therapy R&D and production. Exposure is indirect.

Relevant ETFs (optional – labeled)

ETFs

There is no widely recognized pure-play “stem cell only” ETF. The funds below offer broader genomics or biotech exposure and may hold some regenerative / cell-therapy names among many other holdings.

Always read each ETF’s prospectus and current holdings – composition changes over time.

Formerly public / watch (not investable listings)

Watch only

Private companies frequently mentioned in stem-cell news (e.g., BlueRock/Bayer, Aspen Neuroscience, Neurona, Orca Bio, Gameto) are not listed above because they are not publicly traded.

Investor-assist extras

Key catalysts to watch

• Regulatory decisions: FDA/EMA approvals, Complete Response Letters, PDUFA dates, advisory committee votes (e.g., Capricor deramiocel review path; label expansions for approved products such as Mesoblast’s Ryoncil).
• Late-stage clinical readouts: Phase 2/3 primary endpoints, durability of response, and safety (infections, tumorigenicity, ectopic tissue, immune rejection).
• Partnerships & BD: Big Pharma option exercises, co-development deals (e.g., Lineage-Roche/Genentech on OpRegen), manufacturing alliances.
• Commercial traction: For rare approved products – patient starts, reimbursement, center activation, and gross-to-net dynamics.
• Financing & listing compliance: Cash runway, ATM/equity raises, reverse splits, Nasdaq minimum-bid / equity notices (common among microcap cell-therapy names).
• Manufacturing scale-up: Lot consistency, comparability after process changes, and CMC hold-ups – frequent gating items for cell therapies.

How to follow the space

• ClinicalTrials.gov: Search by intervention (mesenchymal stem cells, iPSC, oligodendrocyte progenitor, company product codes) and by condition; filter by Phase and “Interventional.”
• SEC EDGAR: 10-K/10-Q risk factors, cash runway, and 8-K trial/FDA updates; for foreign issuers also check home-exchange filings (e.g., Mesoblast ASX).
• Conferences: ISSCR, ARM Meeting on the Mesa, ASGCT, ISCT, AAOS (ortho/regen), AHA/ACC (cardiac regen), AAO (ophthalmic cell therapy), World Stem Cell Summit / regenerative medicine investor days.
• Primary sources: Company IR slides, FDA approval letters / labels, peer-reviewed publications (NEJM, Nature Medicine, Lancet, Stem Cell Reports) – prefer these over social-media summaries.

Risk factors specific to stem-cell biotech

• Binary clinical risk: Single trial failures can erase most of a microcap’s value.
• Regulatory pathway complexity: CMC, potency assays, and long-term follow-up for cell products differ from small-molecule drugs.
• Manufacturing & cost of goods: Autologous products are personalized and costly; allogeneic “off-the-shelf” faces immune and scale challenges.
• Dilution: Repeated equity raises are common before profitability.
• Scientific vs. marketing hype: Unapproved clinic offerings and promotional claims have historically hurt the field’s reputation – focus on regulated trials.
• Competition & IP: Overlapping cell sources, delivery methods, and gene-edit IP disputes.
• Listing & liquidity risk: Delistings (see BrainStorm, historical Athersys) and illiquid OTC trading.

Optional Glossary

Sources & method notes

• Listing status cross-checked against recent market quotes and company/SEC disclosures as of September 16, 2026 (ET).
• Pipeline descriptions summarized from company IR materials, ClinicalTrials.gov references, and reputable press (FDA approval notices, peer-reviewed trial reports). Pipelines evolve; verify on primary sources.
• Market-size dollar figures are intentionally omitted here. Published “stem cell market” estimates vary widely by definition (therapy-only vs. broader tools/services). Prefer qualitative context over conflicting third-party forecasts unless citing a specific, dated report the publisher has reviewed.
• StemCellHistory.com Glossary

Educational content only – not investment advice.